Description

Acalataz Capsules 100 mg contain Acalabrutinib 100 mg, a targeted anticancer medicine used for the treatment of specific B-cell blood cancers. It belongs to a class of medicines known as Bruton's Tyrosine Kinase (BTK) inhibitors, which work by blocking the BTK protein responsible for the growth and survival of abnormal B-cells. This action helps slow or stop the progression of certain blood cancers. Key Benefits Targeted therapy for B-cell malignancies Helps slow cancer cell growth and spread May improve progression-free survival in eligible patients Oral capsule for convenient at-home treatment under specialist supervision Indications Acalataz (Acalabrutinib) 100 mg is prescribed for adults with: Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL) Mantle Cell Lymphoma (MCL), in appropriate treatment settings as determined by the treating oncologist. How It Works Acalabrutinib selectively inhibits Bruton's Tyrosine Kinase (BTK), an enzyme involved in B-cell receptor signaling. Blocking BTK prevents cancerous B-cells from receiving growth and survival signals, reducing their multiplication and promoting cancer control. Dosage Strength: 100 mg Dosage should be taken exactly as prescribed by an oncologist. Swallow the capsule whole with water. It may be taken with or without food. Do not crush, chew, or open the capsule. Possible Side Effects Some patients may experience: Headache Fatigue Diarrhea Muscle or joint pain Bruising or bleeding Upper respiratory tract infections Low blood cell counts Seek immediate medical attention if severe bleeding, persistent fever, irregular heartbeat, or signs of infection occur. Precautions Use only under the supervision of a qualified oncologist. Inform your doctor about all medicines you are taking, especially blood thinners and CYP3A-interacting drugs. Regular blood tests may be required during treatment. Avoid use during pregnancy unless specifically advised by your healthcare provider. Breastfeeding is generally not recommended during treatment